Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

Gastroenterology

Volumn 151, Issue 1, 2016, Pages 110-119

  Julsgaard, Mette ^a,c   Christensen, Lisbet A ^a   Gibson, Peter R ^d   Gearry, Richard B ^e   Fallingborg, Jan ^f   Hvas, Christian L ^a   Bibby, Bo M ^a   Uldbjerg, Niels ^b   Connell, William R ^c   Rosella, Ourania ^d   Grosen, Anne ^a   Brown, Steven J ^c   Kjeldsen, Jens ^g   Wildt, Signe ^h   Svenningsen, Lise ⁱ   Sparrow, Miles P ^d   Walsh, Alissa ^j   Connor, Susan J ^k   Radford Smith, Graham ^l   Lawrance, Ian C ^m,n   Andrews, Jane M ^o   Ellard, Kathrine ^p   Bell, Sally J ^c   more..

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ HERNING HOSPITAL   (Denmark)

^j ST VINCENT S HOSPITAL   (Australia)

^k LIVERPOOL HOSPITAL   (Australia)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^m UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁿ ST JOHN OF GOD HOSPITAL   (Australia)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p ROYAL NORTH SHORE HOSPITAL   (Australia)

more..

Author keywords

ERA Study; Inflammatory Bowel Diseases; Safety; Vaccination

Indexed keywords

ADALIMUMAB; ALLOPURINOL; ANTIBIOTIC AGENT; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; GASTROINTESTINAL AGENT;

ACUTE OTITIS MEDIA; ANTIBIOTIC THERAPY; ARTICLE; AUSTRALIA; BACTERIAL INFECTION; BIOLOGICAL THERAPY; BIRTH; BLOOD SAMPLING; CELLULITIS; CHICKENPOX; CONTROLLED STUDY; CROHN DISEASE; DATA COLLECTION METHOD; DENMARK; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; EXANTHEMA SUBITUM; FEMALE; HAND FOOT AND MOUTH DISEASE; HUMAN; INFANT; INFECTION; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MONOTHERAPY; MOTHER; MULTICENTER STUDY; NEW ZEALAND; NEWBORN; OBSTETRIC DELIVERY; PNEUMONIA; PREGNANT WOMAN; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT DURATION; ULCERATIVE COLITIS; UMBILICAL CORD; UMBILICAL CORD BLOOD; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ADULT; BLOOD; FETOMATERNAL TRANSFUSION; FETUS BLOOD; INFLAMMATORY BOWEL DISEASES; METABOLISM; PREGNANCY; PREGNANCY COMPLICATIONS;

ADALIMUMAB; ADULT; AUSTRALIA; DENMARK; FEMALE; FETAL BLOOD; GASTROINTESTINAL AGENTS; HUMANS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MATERNAL-FETAL EXCHANGE; MOTHERS; NEW ZEALAND; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 84990047395     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.04.002     Document Type: Article

References (37)

1. 1 Available from: http://www.firstwordpharma.com. Accessed: December 29, 2015.
2. 2 Khanna, R., Bressler, B., Levesque, B.G., et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 386 (2015), 1825–1834.
3. 3 Burisch, J., Pedersen, N., Cukovic-Cavka, S., et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis 20 (2014), 36–46.
4. 4 Vester-Andersen, M.K., Prosberg, M.V., Jess, T., et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 109 (2014), 705–714.
5. 5 Burisch, J., Pedersen, N., Cukovic-Cavka, S., et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 63 (2014), 588–597.
6. 6 Nguyen, G.C., Seow, C.H., Maxwell, C., et al. The Toronto Consensus Statements for the Management of IBD in Pregnancy. Gastroenterology 150 (2016), 734–757.
7. 7 van der Woude, C.J., Ardizzone, S., Bengtson, M.B., et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 9 (2015), 107–124.
8. 8 Nielsen, O.H., Loftus, E.V. Jr., Jess, T., Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med, 11, 2013, 174.
9. 9 Kane, S.V., Acquah, L.A., Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 104 (2009), 228–233.
10. 10 Malek, A., Sager, R., Kuhn, P., et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 36 (1996), 248–255.
11. 11 Mahadevan, U., Wolf, D.C., Dubinsky, M., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11 (2013), 286–292.
12. 12 Cheent, K., Nolan, J., Shariq, S., et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 4 (2010), 603–605.
13. 13 Vohr, B.R., Tyson, J.E., Wright, L.L., et al. Maternal age, multiple birth, and extremely low birth weight infants. J Pediatr 154 (2009), 498–503.
14. 14 Villar, J., Cheikh, I.L., Victora, C.G., et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 384 (2014), 857–868.
15. 15 Boyd, H.A., Basit, S., Harpsoe, M.C., et al. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One, 10, 2015, e0129567.
16. 16 World Health Organization. ICD-10, International Statistical Classification of Diseases and Related Health Problems, volume 2. 2004.
17. 17 Zelinkova, Z., de Haar, C., de Ridder, L., et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 33 (2011), 1053–1058.
18. 18 Summary of product characteristics for Remicade (infliximab). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_product_information/human/000240/WC500050888.pdf. Accessed: December 29, 2015.
19. 19 Summary of product characteristics for Humira (adalimumab). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_product_information/human/000481/WC500050870.pdf. Accessed: December 29, 2015.
20. 20 Bortlik, M., Duricova, D., Machkova, N., et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis 20 (2014), 495–501.
21. 21 Mahadevan, U., Cucchiara, S., Hyams, J.S., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 106 (2011), 214–223.
22. 22 Ben-Horin, S., Yavzori, M., Katz, L., et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8 (2010), 475–476.
23. 23 Ben-Horin, S., Yavzori, M., Kopylov, U., et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 5 (2011), 555–558.
24. 24 Grosen, A., Julsgaard, M., Kelsen, J., et al. Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 8 (2014), 175–176.
25. 25 Julsgaard, M., Norgaard, M., Hvas, C.L., et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease. Scand J Gastroenterol 49 (2014), 958–966.
26. 26 Kane, S., Lemieux, N., The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 100 (2005), 102–105.
27. 27 de Lima, A., Zelinkova, Z., van der Ent, C., et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut, 2015 Epub ahead of print.
28. 28 Casanova, M.J., Chaparro, M., Domenech, E., et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 108 (2013), 433–440.
29. 29 Francella, A., Dyan, A., Bodian, C., et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124 (2003), 9–17.
30. 30 Blencowe, H., Cousens, S., Oestergaard, M.Z., et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379 (2012), 2162–2172.
31. 31 Mahadevan, U., Sandborn, W.J., Li, D.K., et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 133 (2007), 1106–1112.
32. 32 van, L.A., Smits, G., Mollema, L., et al. Varicella zoster virus infection occurs at a relatively young age in The Netherlands. Vaccine 31 (2013), 5127–5133.
33. 33 The Danish National Institute for Health Data and Disease Control (Statens Serum Institut). Available from: http://www.ssi.dk/Service/Sygdomsleksikon/S/Skoldkopper.aspx. Accessed: February 27, 2016.
34. 34 Mahadevan, U., Martin, C.F., Sandler, R.S., et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy (abstr 865). Gastroenterology, 138, 2012, S149.
35. 35 Sheibani, S., Cohen, R., Kane, S., et al. The effect of maternal peripartum anti-TNFalpha use on infant immune response. Dig Dis Sci, 2016 Epub ahead of print.
36. 36 Mahadevan, U., Martin, C.F., Chambers, C., et al. Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO registry (abstr 1). Gastroenterology, 146, 2014, S-1.
37. 37 Mahadevan, U., Martin, C.F., Dubinsky, M., et al. Exposure to anti-TNF-alpha therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry (abstr 960). Gastroenterology, 146, 2014, S-170.